Literature DB >> 9622076

Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism.

M C Larsen1, W G Angus, P B Brake, S E Eltom, K A Sukow, C R Jefcoate.   

Abstract

CYP1B1 and CYP1A1 expression and metabolism of 7,12-dimethylbenz(a)anthracene (DMBA) have been characterized in early-passage human mammary epithelial cells (HMECs) isolated from reduction mammoplasty tissue of seven individual donors. The level of constitutive microsomal CYP1B1 protein expression was donor dependent (<0.01-1.4 pmol/mg microsomal protein). CYP1B1 expression was substantially induced by exposure of the cells to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to levels ranging from 2.3 to 16.6 pmol/mg among the seven donors. Extremely low, reproducible levels of constitutive CYP1A1 expression were detectable in three donors (0.03-0.16 pmol/mg microsomal protein). TCDD inductions were larger for CYP1A1, as compared to CYP1B1, demonstrating substantial variability in the induced levels among the donors (0.8-16.5 pmol/mg). Northern and reverse transcriptase PCR analyses corroborate the donor-dependent differences in protein expression, whereby CYP1B1 mRNA (5.2 kb) was constitutively expressed and was highly induced by TCDD (33-fold). The contributions of CYP1B1 and CYP1A1 to the metabolism of DMBA were analyzed using recombinant human CYP1B1 and CYP1A1, as references, in conjunction with antibody-specific inhibition analyses (anti-CYP1B1 and anti-CYP1A1). Constitutive microsomal activity exhibited a profile of regioselective DMBA metabolism that was characteristic of human CYP1B1 (increased proportions of 5,6- and 10,11-DMBA-dihydrodiols), which was inhibited by anti-CYP1B1 (84%) but not by anti-CYP1A1. TCDD-induced HMEC microsomal DMBA metabolism generated the 8,9-dihydrodiol of DMBA as the predominant metabolite, with a regioselectivity similar to that of recombinant human CYP1A1, which was subsequently inhibited by anti-CYP1A1 (79%). A CYP1B1 contribution was indicated by the regioselectivity of residual metabolism and by anti-CYP1B1 inhibition (25%). DMBA metabolism analyses of one of three donors expressing measurable basal expression of CYP1A1 confirmed DMBA metabolism levels equivalent to that from CYP1B1. The HMECs of all donors expressed similar, very high levels of the aryl hydrocarbon receptor and the aryl hydrocarbon nuclear translocator protein, suggesting that aryl hydrocarbon receptor and aryl hydrocarbon nuclear translocator protein expression are not responsible for differences in cytochrome P450 expression. This study indicates that CYP1B1 is an important activator of polycyclic aromatic hydrocarbons in the mammary gland when environmental chemical exposures minimally induce CYP1A1. Additionally, certain individuals express low levels of basal CYP1A1 in HMECs, representing a potential risk factor of mammary carcinogenesis through enhanced polycyclic aromatic hydrocarbon bioactivation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.

Authors:  Mónica Rivera-Díaz; Miguel A Miranda-Román; Daniel Soto; Mario Quintero-Aguilo; Humberto Ortiz-Zuazaga; María J Marcos-Martinez; Pablo E Vivas-Mejía
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 3.  Polycyclic aromatic hydrocarbons and digestive tract cancers: a perspective.

Authors:  Deacqunita L Diggs; Ashley C Huderson; Kelly L Harris; Jeremy N Myers; Leah D Banks; Perumalla V Rekhadevi; Mohammad S Niaz; Aramandla Ramesh
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2011-10       Impact factor: 3.781

4.  Aryl hydrocarbon receptor in breast cancer—a newly defined prognostic marker.

Authors:  Ryoko Saito; Yasuhiro Miki; Shuko Hata; Kiyoshi Takagi; Shinya Iida; Yuki Oba; Katsuhiko Ono; Takanori Ishida; Takashi Suzuki; Noriaki Ohuchi; Hironobu Sasano
Journal:  Horm Cancer       Date:  2014-02       Impact factor: 3.869

Review 5.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

6.  6-Prenylnaringenin from Hops Disrupts ERα-Mediated Downregulation of CYP1A1 to Facilitate Estrogen Detoxification.

Authors:  Ryan T Hitzman; Tareisha L Dunlap; Caitlin E Howell; Shao-Nong Chen; Günter Vollmer; Guido F Pauli; Judy L Bolton; Birgit M Dietz
Journal:  Chem Res Toxicol       Date:  2020-10-12       Impact factor: 3.739

7.  Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor-negative breast cancer cells.

Authors:  Xiao-Dan Zhao; Ni Dong; Hong-Tao Man; Zhong-Lin Fu; Mei-Hong Zhang; Shuang Kou; Shi-Liang Ma
Journal:  Biomed Rep       Date:  2013-07-22

8.  Women's occupational exposure to polycyclic aromatic hydrocarbons and risk of breast cancer.

Authors:  Derrick G Lee; Igor Burstyn; Agnes S Lai; Anne Grundy; Melissa C Friesen; Kristan J Aronson; John J Spinelli
Journal:  Occup Environ Med       Date:  2019-01       Impact factor: 4.948

Review 9.  Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer.

Authors:  Rachel Stading; Grady Gastelum; Chun Chu; Weiwu Jiang; Bhagavatula Moorthy
Journal:  Semin Cancer Biol       Date:  2021-07-07       Impact factor: 15.707

10.  Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.

Authors:  Ivan Bièche; Igor Girault; Estelle Urbain; Sengül Tozlu; Rosette Lidereau
Journal:  Breast Cancer Res       Date:  2004-03-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.